Edwards Lifesciences Corporation $EW Shares Purchased by Northwestern Mutual Wealth Management Co.

Northwestern Mutual Wealth Management Co. grew its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 1,952.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,149,700 shares of the medical research company’s stock after acquiring an additional 1,093,692 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in Edwards Lifesciences were worth $98,012,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of EW. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Edwards Lifesciences by 278.3% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock valued at $434,318,000 after buying an additional 4,108,270 shares during the last quarter. Viking Global Investors LP purchased a new stake in Edwards Lifesciences in the third quarter valued at approximately $238,688,000. Jennison Associates LLC boosted its position in Edwards Lifesciences by 19.6% in the third quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock valued at $1,085,574,000 after buying an additional 2,287,783 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Edwards Lifesciences by 8.1% in the third quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock valued at $1,478,425,000 after buying an additional 1,423,365 shares during the last quarter. Finally, AQR Capital Management LLC boosted its position in Edwards Lifesciences by 114.5% in the third quarter. AQR Capital Management LLC now owns 2,081,346 shares of the medical research company’s stock valued at $161,055,000 after buying an additional 1,111,139 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insiders Place Their Bets

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 13,000 shares of the company’s stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $80.04, for a total value of $1,040,520.00. Following the sale, the chief financial officer owned 39,699 shares in the company, valued at approximately $3,177,507.96. This represents a 24.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $83.98, for a total value of $85,575.62. Following the completion of the sale, the vice president owned 33,682 shares in the company, valued at approximately $2,828,614.36. This represents a 2.94% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 88,096 shares of company stock worth $7,288,799. Corporate insiders own 0.31% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on EW. Wolfe Research upgraded Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 target price on the stock in a research report on Wednesday, April 1st. UBS Group reiterated a “neutral” rating and issued a $94.00 target price on shares of Edwards Lifesciences in a research report on Wednesday, February 4th. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Monday, April 20th. Stifel Nicolaus set a $110.00 target price on Edwards Lifesciences and gave the company a “buy” rating in a research report on Tuesday, January 20th. Finally, Mizuho set a $95.00 target price on Edwards Lifesciences and gave the company an “outperform” rating in a research report on Monday, April 13th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $95.65.

Edwards Lifesciences Trading Up 0.0%

Edwards Lifesciences stock opened at $81.34 on Friday. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $87.89. The stock’s 50 day simple moving average is $81.50 and its two-hundred day simple moving average is $82.86. The firm has a market cap of $46.84 billion, a PE ratio of 43.27, a P/E/G ratio of 2.04 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The business had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. During the same quarter in the prior year, the firm posted $0.64 EPS. The business’s quarterly revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.